Exxua Prior Authorization Guide: Requirements by Payer (2025–2026)

Exxua (gepirone extended-release) is the first drug approved for major depressive disorder with a 5-HT1A partial agonist mechanism. Every antidepressant approved since 1987 that is routinely listed as a step-therapy prerequisite — fluoxetine, sertraline, escitalopram, venlafaxine, duloxetine — works by inhibiting the serotonin transporter (SERT). Gepirone does not touch SERT. It acts as a partial agonist at serotonergic 5-HT1A receptors, desensitizing the inhibitory autoreceptors that normally brake serotonin neuron firing. The net result is increased serotonergic tone — but through receptor modulation rather than reuptake blockade. That mechanism distinction matters for prior authorization in a specific, practical way: payer step-therapy criteria for antidepressants were written for SSRI/SNRI mechanisms. Requiring a patient who cannot tolerate SSRI-class side effects to fail an SSRI before accessing a drug that achieves its effect through a pharmacologically orthogonal pathway is the step-therapy mismatch this guide is built to address.

This guide covers what makes Exxua PAs different, what each major payer actually requires, how to document bypasses when they apply, and the dispensing and program facts that determine whether an approved PA can even be filled.

Freshness notice: Exxua received FDA approval September 22, 2023 but did not launch commercially until January 20, 2026. Payer policies are actively being developed and many plans still do not have a drug-specific Exxua PA policy — they are managing it through class rules, formulary exceptions, or recently-published antidepressant step therapy updates. Requirements below reflect primary-source research as of July 2026. Verify against each payer’s current published policy before submitting. Policies for Exxua are among the fastest-changing in psychiatry in 2026.

Why Exxua PAs Are Different

Formulary status is the first problem, not step therapy. Most major commercial plans have not yet added Exxua to their formulary as a covered drug with standard PA requirements. UHC’s commercial PDL effective January 2026 does not list Exxua or gepirone at all — while peer drugs (Auvelity, Trintellix, Viibryd) appear with step-therapy flags. Plans in this position route Exxua through a formulary exception process, which is a different workflow from routine prior authorization. For those plans, the question isn’t “which prior drugs satisfy the step” but “why is this medically necessary when formulary alternatives exist.”

The SSRI/SNRI step-therapy mismatch. Step-therapy criteria for antidepressants assume SSRI/SNRI mechanism equivalence. They don’t account for a drug that achieves antidepressant effect through 5-HT1A receptor modulation rather than SERT blockade. A patient who cannot tolerate SSRIs due to sexual dysfunction, weight gain, or SSRI discontinuation syndrome has failed drugs at the receptor level — those failures are genuine, they satisfy the “prior antidepressant trial” gate at payers who ask for it, and they support the clinical argument for a mechanistically distinct alternative.

Dispensing is limited and must be confirmed before PA. Exxua is not available at CVS, Walgreens, Rite Aid, or most major retail chains. It is dispensed exclusively through the Aytu RxConnect network of approximately 1,000 participating independent and specialty pharmacies. An approved PA that the patient takes to a standard retail pharmacy will not be filled. Verify RxConnect pharmacy availability in the patient’s area before — or simultaneously with — submitting the PA. Contact Aytu RxConnect at 1-888-298-8792.

The QTc issue changes documentation requirements. Gepirone prolonged the QTc interval by approximately 16–18 ms versus placebo in a thorough QT/QTc study. The FDA prescribing information requires a baseline ECG before initiating Exxua. Some payers (BCBS Arizona, and others) have codified this as a PA gate. Any patient with a QTc >450 ms at baseline is not a candidate — and at Centene, a baseline QTc >450 ms is a hard denial criterion regardless of other PA documentation.

FDA Approval and Indication

Approved: September 22, 2023 (NDA 021164)

Commercial launch: January 20, 2026 (Aytu BioPharma, Inc.)

Indication: Major depressive disorder (MDD) in adults

Original applicant: Fabre-Kramer Pharmaceuticals, Inc.

Drug class: Azapirone — 5-HT1A partial agonist. No serotonin transporter (SERT) inhibition. No dopamine D2 blockade. No histamine H1 antagonism. No 5-HT2C antagonism. Mechanism: partial agonist at somatodendritic 5-HT1A autoreceptors → autoreceptor desensitization → increased serotonergic neuron firing → antidepressant effect.

Formulation: Extended-release tablets in four strengths:

• 18.2 mg (starting dose)
• 36.3 mg
• 54.5 mg
• 72.6 mg (target/maintenance dose)

Dosing and titration: 18.2 mg once daily with food for the first week; increase at weekly intervals as tolerated — 36.3 mg, then 54.5 mg, then 72.6 mg. All doses taken once daily with food (food required — exposure increases significantly with food). Maximum dose: 72.6 mg once daily.

Dominant adverse effect — dizziness: Dizziness was reported in approximately 49% of patients receiving gepirone versus 10% on placebo in clinical trials. This is the primary tolerability concern and is the reason titration should proceed gradually. Nausea (14% vs 5%), insomnia (11% vs 5%), and anxiety (10% vs 5%) were also more common than placebo.

QTc prolongation: A dedicated thorough QT/QTc study demonstrated mean QTc prolongation of approximately 16–18 ms at therapeutic doses versus placebo. A baseline ECG is required before initiating Exxua. Contraindicated in patients with QTc >450 ms, congenital long QT syndrome, uncorrected hypokalemia, or uncorrected hypomagnesemia.

Sexual function: Sexual dysfunction terms (decreased libido, orgasm disorder, ejaculatory dysfunction) are not listed as adverse reactions in the Exxua prescribing information. This is mechanistically consistent — SSRI-induced sexual dysfunction is mediated by SERT inhibition, and Exxua does not inhibit SERT.

Weight: Weight increased was reported in 3% of gepirone-treated patients versus 1% on placebo — a small signal, not clinically comparable to SSRI/SNRI-associated weight gain.

Exclusivity: New Chemical Entity (NCE) exclusivity through September 2028. No generic alternative until at least that date.

What Exxua is NOT approved for: Generalized anxiety disorder, social anxiety disorder, panic disorder, or other anxiety conditions (gepirone was studied in anxious depression across decades of trials but these are not approved indications). Pediatric patients. Adjunctive use — not studied as an add-on to other antidepressants. Buspirone comparison — buspirone is the same azapirone pharmacological class but its FDA-approved indication is generalized anxiety disorder, not MDD. Exxua and buspirone are not interchangeable.

Dispensing: Aytu RxConnect

Exxua is dispensed exclusively through the Aytu RxConnect limited distribution network.

• Not available at: CVS, Walgreens, Rite Aid, Kroger, or most major retail chains
• Available at: Approximately 1,000 participating independent and specialty pharmacies
• Phone: 1-888-298-8792
• Copay assistance: Aytu RxConnect patient copay program available for eligible commercially-insured patients — NOT available to Medicare, Medicaid, or government-sponsored insurance beneficiaries
• WAC: Approximately $1,500–$1,800 per month (30 tablets)

Before submitting a PA for any payer, call 1-888-298-8792 to confirm there is a participating RxConnect pharmacy within reasonable distance of the patient. A PA approval is worthless if there is no pharmacy that can fill it.

Diagnosis Documentation

Required ICD-10 codes for Exxua’s FDA-approved indication (MDD in adults):

NOT appropriate: F41.x (anxiety disorders — not FDA-approved). F31.x (bipolar disorder — not approved). F25.x (schizoaffective disorder — not approved). Any anxiety diagnosis will result in automatic denial; Exxua has no approved anxiety indication despite the drug’s long development history in anxiety conditions.

Contraindications That Affect PA

Document any of the following before submitting — they are PA gates at multiple payers:

Coverage Summary

Payer-Specific Requirements

Cigna / Evernorth

Policy: CNF_864 — Antidepressants Step Therapy Policy (last reviewed 05/13/2026). Exxua added to CNF_864 in the November 12, 2025 revision.

Which plans are covered by CNF_864: CNF_864 is the national formulary coverage policy for Cigna commercial and employer plans that use Cigna’s CNF (National Formulary Coverage) formulary. Plans governed by the legacy pharmacy policy series (ph_1801, ph_1802, ph_1803) may not list Exxua at all — Auvelity is the Step 3 antidepressant in those documents, and Exxua’s absence means those plan members would need a formulary exception. Confirm which policy applies to the patient’s plan before submitting.

Step 2 requirements under CNF_864:

Standard criteria (most commercial plans) — requires ONE prior Step 1 product:

Step 1 generics include: generic bupropion ER tablets, generic bupropion SR tablets, generic citalopram (oral solution or tablets), generic duloxetine delayed-release capsules (20 mg, 30 mg, 60 mg), generic escitalopram tablets, generic fluoxetine immediate-release capsules or oral solution, generic fluvoxamine immediate-release tablets, generic paroxetine HCl immediate-release tablets, generic sertraline oral solution or tablets, generic venlafaxine ER capsules, generic venlafaxine IR tablets.

Any one of these Step 1 generics satisfies the standard criteria. Minimum trial duration is not specified in CNF_864 — the policy language states “tried,” not “adequate trial at maximum dose.” A brief trial discontinued due to adverse effects qualifies.

High Impact criteria (higher-restriction plan designs) — requires TWO prior Step 1 products.

Bypass conditions (both Standard and High Impact):

• Patient currently taking Exxua, or has taken Exxua at any time in the past → approve without step therapy
• Patient has suicidal ideation → approve Exxua without step therapy

Important: CNF_864 does not list SSRI/SNRI intolerance as an explicit named bypass — unlike some BCBS plans. However, because the policy requires only that the patient have “tried” a Step 1 product, a patient who tried sertraline and stopped due to sexual dysfunction has, by that fact, tried a Step 1 drug. The intolerance effectively satisfies the step without needing a named bypass.

Authorization duration: 1 year for all approvals.

UnitedHealthcare / OptumRx

Status: Exxua does not appear in the UnitedHealthcare Commercial formulary effective January 1, 2026. A line-by-line extraction of the 5,068-line UHC PDL confirmed that neither “Exxua” nor “gepirone” appears. Peer antidepressants (Auvelity, Trintellix, Fetzima, Viibryd) are listed with step therapy and quantity limit flags. Exxua’s absence means the drug is currently managed as non-formulary for most UHC commercial plans.

No primary-source UHC PA policy for Exxua exists as of the date of this research. Payer intelligence suggests UHC has been adding Exxua to its step therapy program through 2026 plan year updates, but no document with a specific step count or bypass criteria was verified from UHC primary sources. Do not rely on secondhand characterizations of “UHC requires 2-3 antidepressant failures” without verifying the current UHC published policy.

Workflow for UHC non-formulary: Submit a formulary exception request (not a standard prior authorization). The formulary exception form requires documentation of:

• Medical necessity for Exxua specifically over formulary alternatives
• Clinical rationale why the patient is not a candidate for formulary antidepressants
• Prior antidepressant trial history with outcomes

Call OptumRx Formulary Exception at 1-800-711-4555 for drug-specific clinical guideline information, which may not be publicly posted.

OptumRx specialty pharmacy routing: Exxua is not routed through OptumRx specialty pharmacy by payer policy — the manufacturer’s RxConnect network restriction applies independently.

Aetna / CVS Caremark

Status: Exxua is classified as non-preferred brand (NPB) or non-formulary on most Aetna commercial plans. No dedicated clinical policy bulletin (CPB) for Exxua was confirmed from Aetna’s primary sources as of this research. PA requirements are applied through Aetna’s general antidepressant class rule.

Approximate step therapy: Two prior antidepressant failures from standard SSRI/SNRI classes. This is inferred from the class rule, not verified from an Exxua-specific policy. Confirm directly with Aetna for the patient’s specific plan.

180-day auto-pay rule does NOT apply: Aetna/CVS Caremark’s 6688-D policy (which provides automatic payment for established antipsychotic patients) covers antipsychotics, not antidepressants. This rule — which was relevant for Cobenfy — does not apply to Exxua and should not be cited in Exxua PA submissions.

Pharmacy routing: CVS Caremark routing applies for pharmacy benefit claims. Exxua’s dispensing through the Aytu RxConnect network (independent/specialty pharmacies) is manufacturer-imposed and operates separately from CVS Caremark’s specialty pharmacy mandate.

FEP Blue: Federal Employee Program members under Aetna or BCBS routing should expect non-formulary status and separate exception criteria via their CVS Caremark benefit administrator.

Blue Cross Blue Shield of Arizona (Commercial / Marketplace)

Policy: Pharmacy Coverage Guideline P370, effective November 20, 2025. Applies to BCBS AZ commercial and Marketplace plans only — explicitly excludes Medicare Advantage, Medicaid, and Federal Employee Program.

Step therapy — closed list, cross-class requirement: Exxua requires prior failure, intolerance, or documented contraindication to:

• One SSRI from the following closed list: citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline
• AND one SNRI from the following closed list: desvenlafaxine, duloxetine, venlafaxine, venlafaxine ER

Both class requirements must be satisfied — failure of two SSRIs without an SNRI trial does not satisfy the criteria.

Additional required documentation at BCBS AZ:

• Prescriber must be a psychiatrist or in consultation with a psychiatrist
• Baseline ECG must be obtained before initiating Exxua
• QTc must be confirmed <450 ms (screen result required)
• Potassium and magnesium abnormalities must be corrected prior to initiation
• Screening for bipolar disorder, mania, or hypomania history is required (Exxua is not approved for bipolar depression; manic switch risk must be assessed)

Quantity limit: Not specified in P370 (Premera and Centene both set QL at 1 tablet/day).

Authorization duration: 6 months initial; 12 months for renewals.

Note on sample counts: Samples do not count as evidence of prior adequate trial under BCBS AZ’s criteria.

Premera Blue Cross

Policy: Clinical Review Criteria 5.01.520.

Step therapy: 2 prior generic antidepressant failures required. Specific drug class composition not specified as cross-class (any two generics satisfy the requirement, in contrast to BCBS AZ’s mandatory SSRI + SNRI cross-class structure).

Quantity limit: 1 tablet per day; maximum 72.6 mg per day. Quantity aligns with the FDA maximum dose.

Authorization duration: Up to 12 months.

BCBS Texas (HCSC) / Florida Blue / Wellmark BCBS (Prime Therapeutics)

BCBS Texas (Health Care Service Corporation), Florida Blue, and Wellmark BCBS (Iowa/South Dakota) all use Prime Therapeutics as their PBM and share the NetResults Antidepressants Step Therapy with Quantity Limit program, effective April 1, 2026.

Step therapy — one prior antidepressant required:

Any ONE generic antidepressant from an open list: SSRI, SNRI, bupropion, mirtazapine, or vilazodone. A medication history of use within the past 365 days satisfies the requirement — no minimum trial duration is specified.

180-day auto-approval: Patients with Exxua fill history within the past 180 days are automatically approved without step therapy review.

Bypass conditions: Documented intolerance or hypersensitivity to one prerequisite agent. If all prerequisite agents are contraindicated, the step therapy requirement is waived.

No prescriber requirement: Unlike BCBS AZ, there is no psychiatrist attestation requirement.

Quantity limit: 30 tablets per 30 days (for 36.3 mg, 54.5 mg, and 72.6 mg strengths); 32 tablets per 30 days for the 18.2 mg titration strength.

Authorization duration: 12 months.

No specialty pharmacy routing: Prime Therapeutics does not route Exxua through specialty pharmacy. Dispensing follows the Aytu RxConnect retail model.

Note: BCBS Massachusetts, Highmark commercial, Anthem/Elevance, FEP Blue, and some other regional BCBS plans treat Exxua as non-formulary or have criteria behind authenticated member portals that were not accessible for primary-source verification. Anthem/Elevance Health confirmed off-formulary with an exception pathway from Anthem’s 2026 commercial formulary. FEP Blue confirmed not covered (absent from the 2026 FEP national formulary; 14,882-line text extraction, zero hits). BCBS Michigan confirmed step therapy with 3 prior failures required. Verify current formulary status directly with any BCBS regional plan not covered above.

Centene / Ambetter / Health Net / WellCare

Policy: CP.PMN.292 — Gepirone (Exxua). Effective date: December 1, 2023. Lines of business: Commercial, Health Insurance Marketplace (HIM), Medicaid.

Step therapy — two failures required:

Two prior antidepressant failures are required, each meeting the following duration standard: ≥4 weeks at up to the maximally indicated dose, unless clinically significant adverse effects occur or the drug is contraindicated.

The five eligible drug classes/agents from which the two failures must come:

• SSRI (any SSRI)
• SNRI (any SNRI)
• Bupropion
• Mirtazapine
• Vilazodone

Any combination of two from this list satisfies the requirement. Unlike Cobenfy’s mandatory aripiprazole requirement, there is no single mandatory drug for Exxua — a patient who failed sertraline and venlafaxine, or fluoxetine and bupropion, satisfies the step.

Adverse effects exception: If clinically significant adverse effects occur during a required trial, that trial counts even if it did not reach 4 weeks at maximum dose. Document the adverse effect (e.g., sexual dysfunction on SSRI, significant weight gain, insomnia, nausea) explicitly in the PA submission.

All-contraindicated exception: If all agents on the step-therapy list are contraindicated, the step therapy requirement is waived entirely.

QTc hard stop — not a bypass: Patients with QTc >450 ms at baseline or diagnosed with congenital long QT syndrome are not candidates for Exxua under CP.PMN.292. This is not a bypass condition — it is a denial criterion. Unlike some contraindications that can be used to argue for a non-standard drug, QTc >450 ms results in denial regardless of PA documentation quality.

State step-therapy reduction — Texas (HIM plans only): Texas state law restricts step therapy requirements for mental health drugs in certain contexts. For Texas Marketplace/HIM plan members, Centene reduces the requirement to one prior antidepressant failure (instead of two). Other states with similar protections are tracked in Centene’s internal Appendix D.

Medicaid: CP.PMN.292 covers Medicaid lines of business, but Medicaid PDL tier and PA status vary by state. Specific state Medicaid formulary placement was not confirmed in this research.

Authorization duration: 12 months.

Medicare Part D

Protected class status: Antidepressants are one of the six protected drug classes under Medicare Part D, codified at 42 CFR § 423.120(b)(2) and originating from Section 1860D-4(b)(3)(G)(iv) of the Social Security Act. All Part D plans must include antidepressants on their formulary.

PA and step therapy for new starts: Protected class status does not mean PA-free. The regulation at 42 CFR § 423.120(b)(2)(vi)(C) permits prior authorization and step therapy for new starts, including for protected class drugs, “to confirm intended use is for a protected class indication, to ensure clinically appropriate use, or to promote utilization of preferred formulary alternatives.” Plans may impose step therapy for a patient requesting Exxua who has not previously been on the drug.

Established patient continuity: Plans cannot interrupt or restrict access for patients already stabilized on Exxua. New-to-plan enrollees who are currently taking Exxua must receive continuity of coverage while a coverage determination is pending.

Tier placement: BCBS Alabama Medicare 2026 confirmed Exxua at Tier 5 (specialty/non-preferred brand tier) with a quantity limit of 30 tablets per 30 days. Tier 5 placement is standard for newly launched specialty-tier branded drugs; other Part D plans are expected to follow similar placement.

2026 Part D cost-sharing structure:

Extra Help / Low Income Subsidy copays:

After the $2,100 OOP cap, copay = $0 for all Part D enrollees.

Copay assistance programs: The Aytu RxConnect patient copay program is not available to Medicare, Medicaid, or government-sponsored insurance beneficiaries. Counsel Medicare patients on Extra Help enrollment (www.medicare.gov/extra-help) if cost is a barrier.

Antidepressants vs. antipsychotics protection note: Antidepressants and antipsychotics are treated identically under the CMS-4180-F established-patient protection framework. Antiretrovirals (HIV medications) have a stricter protection where PA is never permitted even for new starts — that level of protection does not apply to antidepressants.

The SSRI/SNRI Step-Therapy Mismatch

Payer step-therapy requirements for antidepressants were constructed around the observation that SSRIs and SNRIs are clinically equivalent first-line options — generic, well-tolerated, and cost-effective. Requiring trial of a cheap generic before an expensive branded drug is a defensible utilization management strategy within that framework.

Exxua breaks this framework at the mechanism level. The clinical case for bypassing or satisfying step therapy faster than the payer’s default assumptions:

Mechanism bypass argument: “Exxua’s antidepressant effect operates through 5-HT1A partial agonism — autoreceptor desensitization that modulates serotonergic neuron firing rate. This mechanism is pharmacologically distinct from SERT inhibition. Requiring failure of an SSRI before prescribing a drug that does not inhibit SERT is analogous to requiring failure of a beta-blocker before prescribing a calcium channel blocker — both address the same physiological system but through unrelated molecular targets.”

SSRI-induced sexual dysfunction: Sexual dysfunction (decreased libido, anorgasmia, delayed ejaculation) is a class effect of SERT inhibition — not a side effect that appears at a specific SSRI dose or can be titrated away. A patient who discontinued an SSRI due to sexual dysfunction has a documented reason to prefer a drug without SERT activity. That SSRI trial is a genuine prior failure that satisfies step-therapy gates at most payers, and the sexual dysfunction documentation supports the necessity argument where formulary exception is required.

SSRI-induced weight gain: Paroxetine and several SSRIs are associated with significant weight gain over long-term use. Weight gain documented on a prior SSRI trial is an adverse effect that cuts the trial short (satisfying adverse-effects exceptions at Centene) and supports medical necessity for a mechanistically distinct alternative.

No SERT rebound on discontinuation: Patients who have experienced discontinuation syndrome (dizziness, electric-shock sensations, anxiety) when stopping SSRIs have encountered a known consequence of rapid reduction in synaptic serotonin from SERT inhibition withdrawal. Because Exxua does not inhibit SERT, it does not share this rebound mechanism — though this claim is mechanistic inference, not a statement from the FDA prescribing information, and should not appear on a PA form as a label claim.

QTc limitation on further SSRI/SNRI trials: If prior SSRI or SNRI use contributed to QTc prolongation, further trials of the same drug class carry ongoing cardiac risk. If the patient’s baseline QTc is below 450 ms but elevated (e.g., 420–440 ms), document this as a clinical reason for avoiding drugs with additive QTc risk.

Tips for First-Pass Approval

1. Confirm RxConnect pharmacy before submitting PA. Call 1-888-298-8792 to verify a participating pharmacy is accessible to the patient. A PA approval cannot be filled at CVS or Walgreens.

2. Get the baseline ECG first. BCBS AZ requires documented ECG with QTc <450 ms. Even for plans that don’t mandate it, having ECG documentation ready shortens peer-to-peer and reduces appeal risk.

3. Document all prior antidepressant trials with specificity. Include drug name, dose reached, duration of trial, and documented reason for discontinuation (adverse effect, inadequate response, or contraindication). Vague entries (“tried Zoloft, didn’t tolerate”) are more likely to trigger peer-to-peer requests than detailed entries (“sertraline 200 mg × 6 weeks; discontinued due to complete anorgasmia and 14-lb weight gain”).

4. Correct potassium and magnesium before submitting to BCBS AZ. BCBS AZ’s P370 requires documented correction of electrolyte abnormalities before approving Exxua. Have labs ready.

5. For Cigna CNF_864 plans: one prior generic SSRI/SNRI is enough. CNF_864 Standard criteria require only one Step 1 generic. The trial does not require a minimum duration — “tried” is the standard. A patient who tried escitalopram for two weeks and stopped due to sexual dysfunction has satisfied the Cigna step.

6. For patients with suicidal ideation (Cigna): document it explicitly. CNF_864 lists suicidal ideation as a bypass condition that approves Exxua without step therapy. If suicidal ideation is present and clinically documented, include it in the PA submission.

7. For Centene: the adverse effects exception is a first-line argument, not a fallback. CP.PMN.292 requires two trials but explicitly waives the 4-week minimum if clinically significant adverse effects occur. A patient who tried an SSRI for one week and stopped due to severe nausea or acute sexual dysfunction has a documented adverse-effects exception that shortens the trial requirement.

8. Screen for bipolar disorder before submitting to BCBS AZ. BCBS AZ’s P370 requires documentation of the screening. An un-screened submission will be denied or sent to peer-to-peer. Screen and document before submitting.

9. Include psychiatrist attestation for BCBS AZ. BCBS AZ requires the prescriber to be a psychiatrist or to have consultation documentation from one. If the prescribing clinician is a PCP or NP, obtain and attach a psychiatry consultation note.

10. For UHC: submit formulary exception, not standard PA. Because Exxua is not on the UHC commercial PDL, the route is formulary exception — a different form and a different review path from a standard PA. Submitting as a standard PA may result in an administrative denial before clinical review begins.

11. Do not use F41.x (anxiety) ICD-10 codes. Exxua is not approved for anxiety disorders. Any anxiety-class diagnosis code as the primary indication will result in automatic denial. Use F32.x or F33.x only.

12. Counsel Medicare patients on Extra Help before the first fill. The Aytu RxConnect copay card is not available to Medicare beneficiaries. The OOP cap of $2,100 provides substantial protection, but at Tier 5 with 25% coinsurance and a $615 deductible, the first few fills will have significant cost-sharing before the cap is reached. Medicare Savings Programs and Extra Help enrollment can reduce this substantially.

When PA Fails: Appeals Framework

State step-therapy override statutes: Most states with commercial insurance regulation have enacted step-therapy override laws for mental health conditions that allow the treating clinician to request a bypass when the standard step-therapy protocol is clinically inappropriate. These laws apply to fully-insured commercial plans regulated by the state. ERISA self-funded employer plans are not subject to state override laws. Confirm plan type (fully-insured vs. self-funded) before relying on a state override argument.

Peer-to-peer: Request a peer-to-peer review with the payer’s medical director when the initial appeal is denied. The mechanism distinction argument (5-HT1A agonism vs. SERT inhibition) and the sexual dysfunction/weight/discontinuation syndrome documentation should be framed in that call. Documenting suicidal ideation (at Cigna) or a state mental health step-therapy override claim (at applicable fully-insured plans) in that call can change the outcome.

Primary Sources

1. FDA Exxua prescribing information (NDA 021164) — DailyMed, accessdata.fda.gov
2. Cigna CNF_864 — Antidepressants Step Therapy Policy (last reviewed 05/13/2026) — static.cigna.com
3. Cigna ph_1801 — Standard/Performance PDL employer group step therapy policy — static.cigna.com
4. Cigna ph_1803 — Legacy PDL employer group step therapy policy — static.cigna.com
5. Blue Cross Blue Shield of Arizona Pharmacy Coverage Guideline P370 — effective 11/20/2025 — formularynavigator.com
6. Premera Blue Cross Clinical Review Criteria 5.01.520 — premera.com
7. Centene CP.PMN.292 — Gepirone (Exxua) — effective 12/1/2023 — healthnet.com, superiorhealthplan.com, ambetterhealth.com
8. UnitedHealthcare Commercial Formulary (PDL), effective January 1, 2026 — uhcprovider.com (text extraction confirmed Exxua/gepirone absent)
9. BCBS Alabama Medicare 2026 Formulary — Tier 5 placement confirmed — bcbsalmedicare.com
10. 42 CFR § 423.120(b)(2) — Protected drug classes (antidepressants), PA/step therapy permissions — ecfr.gov
11. CMS Final CY2026 Part D Redesign Program Instructions — cms.gov
12. Aytu BioPharma 8-K (January 20, 2026) — commercial launch announcement — sec.gov
13. Aytu RxConnect Provider Guide — medfinder.com
14. Iowa Medicaid PDL committee recommendation, February 2026 — Non-Preferred with Conditions